Cost-Effectiveness Analysis of Camrelizumab Immunotherapy versus Docetaxel or Irinotecan Chemotherapy as Second-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Lin YT, Chen Y, Liu TX, Kuang F, Huang P

Cancer Management and Research 2021, 13:8219-8230

Published Date: 2 November 2021